A larger study with longer follow-up concluded that "use of DMPA during pregnancy or breastfeeding does not adversely affect the long-term growth and development of children". This study also noted that "children with DMPA exposure during pregnancy and lactation had an increased risk of suboptimal growth in height," but that "after adjustment for socioeconomic factors by multiple logistic regression, there was no increased risk of impaired growth among the DMPA-exposed children." The study also noted that effects of DMPA exposure on puberty require further study, as so few children over the age of 10 were observed. 
Q. Had FMS for almost twenty years now, tried almost everything. Is Lyrica in the "steroid" family? Any one in this community could help me? I have given my few questions to find out an answer. I Had FMS for almost twenty years now, tried almost everything. I'm considering Lyrica but I'd like more info. Is Lyrica in the "steroid" family? If you go on Lyrica for a while & see no improvement with pain, is going off of it a big deal like with other med's, or can you simply just stop taking it? I take Ambien, will that have any interactions? I'm seeing my Doc about this at the end of the month, but I was hoping to get some personal experiences about it. Thanks for any thoughts! Thanks for your answers, keep them coming! A. according to this-
there is a moderate interaction. that means you can take them both but be checked regularly for depression of breath.
Secondary efficacy endpoints evaluated included objective tumor response, assessed by clinical evaluations of tumor burden (complete response, partial response, objectively stable, and progression), as well as changes in local disease status, assessed by digital rectal examination, and changes in prostatic acid phosphatase (PAP). These evaluations were performed at Weeks 12 and 24. The objective tumor response analysis showed a “no progression” (ie. complete or partial response, or stable disease) in 77% (40/52) of patients at Week 12, and in 84% (42/50) of patients at Week 24. Local disease improved or remained stable in all (42) patients evaluated at Week 12 and in 98% (41/42) of patients elevated at Week 24. PAP normalized or decreased at Week 12 and/or 24 in the majority of patients with elevated baseline PAP.